- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARCELLX Aktie jetzt für 0€ handeln | |||||
| 10.12. | Safety Stands Out in Arcellx Cell Therapy's ASH Data, But Don't Overlook Manufacturing Advantages | 3 | MedCity News | ||
| 09.12. | In-Depth Examination Of 14 Analyst Recommendations For Arcellx | 2 | Benzinga.com | ||
| 09.12. | Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. | 4 | Investor's Business Daily | ||
| 09.12. | 14 Analysts Have This To Say About Arcellx | 1 | Benzinga.com | ||
| 09.12. | Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients | 3 | Benzinga.com | ||
| 09.12. | Arcellx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | Arcellx-Direktorin Kavita Patel verkauft Aktien im Wert von 159.495 US-Dollar | 2 | Investing.com Deutsch | ||
| 08.11. | Analyst Expectations For Arcellx's Future | 7 | Benzinga.com | ||
| 08.11. | Arcellx GAAP EPS of -$0.48, revenue of $26.03M | 9 | Seeking Alpha | ||
| 07.11. | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | 113 | Business Wire | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| 07.11. | Arcellx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Arcellx stock soars to all-time high of $97.61 amid robust growth | 2 | Investing.com | ||
| 07.11. | Arcellx-Aktie erreicht Allzeithoch von 97,61 US-Dollar | 4 | Investing.com Deutsch | ||
| 06.11. | Navigating 7 Analyst Ratings For Arcellx | 1 | Benzinga.com | ||
| 06.11. | Arcellx to present positive data on multiple myeloma treatments | 2 | PharmaTimes | ||
| 05.11. | ASH: New Gilead-Arcellx data build CAR-T's case against Carvykti in advanced multiple myeloma | 12 | FierceBiotech | ||
| 05.11. | BofA raises Arcellx price target to $100 on positive data | 2 | Investing.com | ||
| 05.11. | BofA erhöht Kursziel für Arcellx auf 100 US-Dollar aufgrund positiver Daten | 3 | Investing.com Deutsch | ||
| 05.11. | Cancer cell therapy from Arcellx, Gilead shows promise in early data | 11 | BioPharma Dive | ||
| 05.11. | Arcellx meldet vielversprechende Ergebnisse für Myelom-Behandlung | 1 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,150 | +3,60 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,402 | +10,14 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,300 | +6,19 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,270 | +3,89 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,230 | +0,79 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 15,490 | -0,06 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,880 | -1,26 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,450 | +0,29 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,920 | -0,17 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,370 | +0,41 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,710 | -0,44 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,980 | +0,48 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,220 | -3,17 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen ARCELLX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 75,13 Euro und damit -0,66 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCELLX INC finden Sie auf Wallstreet Online.
